Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.
BACKGROUND
As is often the case for rare diseases, the number of published reviews and case reports of glucose transporter type I deficiency (G1D) approaches or exceeds that of original research. This can indicate medical interest, but also scientific stagnation.


METHODS
In assessing this state of affairs here, we focus not on what is peculiar or disparate about G1D, but on the assumptions that have reigned thus far undisputed, and critique them as a potential impediment to progress. To summarize the most common G1D phenotype, we trace the 25-year story of G1D in parallel with the natural history of one of two index patients, identified in 1990 by one of us (G.M.R.) and brought up to date by the other (J.M.P.) while later examining widely repeated but little-scrutinized statements. Among them are those that pertain to assumptions about brain fuels; energy failure; cerebrospinal glucose concentration; the purpose of ketogenic diet; the role of the defective blood-brain barrier; genotype-phenotype correlations; a bewildering array of phenotypes; ictogenesis, seizures, and the electroencephalograph; the use of mice to model the disorder; and what treatments may and may not be expected to accomplish.


RESULTS
We reach the forgone conclusion that the proper study of mankind-and of one of its ailments (G1D) -is man itself (rather than mice, isolated cells, or extrapolated inferences) and propose a framework for rigorous investigation that we hope will lead to a better understanding and to better treatments for this and for rare disorders in general.


CONCLUSIONS
These considerations, together with experience drawn from other disorders, lead, as a logical consequence, to the nullification of the view that therapeutic development (i.e., trials) for rare diseases could or should be accelerated without the most vigorous scientific scrutiny: trial and error constitute an inseparable couple, such that, at the present time, hastening the former is bound to precipitate the latter.
Rare Brain Disorders Program, Departments of Neurology and Neurotherapeutics, Physiology and Pediatrics, Eugene McDermott Center for Human Growth and Development/Center for Human Genetics, The University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: Juan.Pascual@UTSouthwestern.edu.
Juan M
JM
Pascual
Department of Pediatrics, McMaster Child Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Gabriel M
GM
Ronen
D000328:Adult; D000818:Animals; D001921:Brain / Q000503:physiopathology; D005260:Female; D051272:Glucose Transporter Type 1 / Q000172:deficiency*; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D035583:Rare Diseases / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy
D051272:Glucose Transporter Type 1
G1D; Glut1 deficiency; blood brain barrier; natural history; triheptanoin